Shared Resource 09: Leukemia Tissue Bank (LTBSR)

项目摘要-白血病组织库共享资源(LTBSR) LTBSR是一个历史悠久的生物库，成立于1997年，负责采购、加工和存储生物 材料来自血液病患者同意的患者。LTBSR通过两种方式获取样本：1)通过 用于未来研究的通用生物库协议；以及2)通过特定的临床研究协议 收集需求。LTBSR的主要服务是患者同意，获取样本(例如血液、骨骼 骨髓和白细胞分离产品)由一般或特定的IRB方案指示，评估样本 高质量，向调查人员提供新鲜样本或对其进行加工储存，提供监督过程 用于样品和数据的使用，并将样品和数据提供给经批准的收件人。调查人员收到 鉴定出表型或遗传特征的样本，以及临床数据和可用的病理数据(包括 护理标准免疫表型和基因测序小组)。在当前周期中，Lapo Alinari博士 (Lr)取代了前LTBSR主任(David Lucas，从哥伦布搬来)和Robert Baiocchi博士(Lr) 取代克拉拉·布卢姆菲尔德(Clara Bloomfield)博士担任高级教师顾问。LTBSR的具体目标是：1) 同意受试者并采集血液病患者的样本；2)统一处理， 使用最先进的程序表征和存储生物样品；以及3)为生物样品提供 向OSUCCC研究人员和外部机构提供相关的临床、病理和基因组数据，以便 他们可以将患者样本的发现与临床或基于人群的结果相关联。在海流之上 在赠款周期内，LTBSR已经支持了67名调查人员(75%的OSUCCC成员)和OSUCCC的全部五名成员 研究方案，45份出版物(11&>10个影响因素)和19个国家合作伙伴赠款，包括1个K12，1个K22，1个K23，1个 P01、13个R01和2个R35。OSUCCC最近承诺大幅增加样本数量 从淋巴瘤患者的淋巴样本中获得。此外，LTBSR还扩展了以下服务 从置换手术中收集废弃的正常髋骨作为骨髓基质细胞的来源 脐带血作为CD34+造血干细胞的来源。在下一个供资周期中，LTBSR将 继续扩大其组织采购服务的广度，解决OSUCCC的研究优先事项 免疫肿瘤学、翻译基因组学、癌症预防和生存。美国政府的年度预算 LTBSR为664,631美元，而CCSG的请求为70,451美元。因此，LTBSR利用了广泛的机构 支持，只寻求CCSG基金10.6%的支持。

PROJECT SUMMARY – LEUKEMIA TISSUE BANK SHARED RESOURCE (LTBSR) The LTBSR is a longstanding biobank, established in 1997, that procures, processes, and stores biologic material from consenting patients with hematologic diseases. The LTBSR procures samples in two ways: 1) via a general biobanking protocol for future research; and 2) via specific clinical research protocols with special collection needs. The major services of the LTBSR are consenting patients, procuring samples (e.g., blood, bone marrow, and leukapheresis products) as directed by the general or a specific IRB protocol, assessing sample quality, providing fresh samples to investigators or processing them for storage, providing an oversight process for use of samples and data, and delivering samples and data to approved recipients. Investigators receive samples identified phenotypically or genetically, along with clinical data and available pathology data (including standard of care immunophenotyping and genetic sequencing panels). During the current cycle, Dr. Lapo Alinari (LR) replaced the prior LTBSR Director (David Lucas, who moved from Columbus), and Dr. Robert Baiocchi (LR) replaced Dr. Clara Bloomfield (LR) as the Senior Faculty Advisor. The Specific Aims of the LTBSR are to: 1) consent subjects and procure samples from patients with hematologic diseases; 2) uniformly process, characterize and store biospecimens using state-of-the art procedures; and 3) provide biospecimens with associated clinical, pathological and genomic data to OSUCCC researchers and to outside institutions so that they can correlate findings from patient samples with clinical or population-based outcomes. Over the current grant cycle, the LTBSR has supported 67 investigators (75% OSUCCC members) and all five of the OSUCCC research programs, 45 publications (11 > 10 impact factor) and 19 NCI grants, including 1 K12, 1 K22, 1 K23, 1 P01, 13 R01s, and 2 R35s. The OSUCCC has recently made a commitment to substantially increase samples obtained by lymph node sampling from lymphoma patients. In addition, the LTBSR has expanded services for collecting discarded normal hipbone from replacement surgeries as a source of marrow stromal cells and umbilical cord blood as a source of CD34+ hematopoietic stem cells. In the next funding cycle, the LTBSR will continue to expand its breadth of tissue procurement services, addressing the OSUCCC research priorities of immuno-oncology, translational genomics, and cancer prevention and survivorship. The annual budget of the LTBSR is $664,631, yet the CCSG request is $70,451. Thus, the LTBSR leverages extensive institutional support and seeks only 10.6% support from CCSG funds.